Trial Profile

A pRospective, Case-controlled Evaluation of oLIceridine for Moderate or sEVEre Pain in Patients With Acute Burn Injuries. (RELIEVE)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 04 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Nov 2023 According to a Trevena, Inc media release, Dosing and assessments were followed per study protocol and safety and efficacy assessed by study team daily at a minimum.
30 Nov 2023 According to a Trevena, Inc media release, this is a investigator-initiated trial and was led by David Hill, PharmD.
30 Nov 2023 According to a Trevena, Inc media release, company announced today acceptance of an abstract presenting results from this trial in patients with acute burn injuries will be presented at the 2024 ABA annual meeting, being held April 9th-12th in Chicago.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com